Cancer Therapy

You have full text access to this OnlineOpen article

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis

  1. Kostantinos Zarogoulidis1,†,*,
  2. Eufimia Boutsikou1,
  3. Pavlos Zarogoulidis1,
  4. Ellada Eleftheriadou1,
  5. Theodore Kontakiotis1,
  6. Hellie Lithoxopoulou1,
  7. George Tzanakakis2,
  8. Ioannis Kanakis3,
  9. Nikos K. Karamanos3,‡,*

Article first published online: 6 APR 2009

DOI: 10.1002/ijc.24470

Issue

International Journal of Cancer

International Journal of Cancer

Volume 125, Issue 7, pages 1705–1709, 1 October 2009

Additional Information

How to Cite

Zarogoulidis, K., Boutsikou, E., Zarogoulidis, P., Eleftheriadou, E., Kontakiotis, T., Lithoxopoulou, H., Tzanakakis, G., Kanakis, I. and Karamanos, N. K. (2009), The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. International Journal of Cancer, 125: 1705–1709. doi: 10.1002/ijc.24470

Author Information

  1. 1

    Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece

  2. 2

    Department of Histology, School of Medicine, University of Crete, Herakleion, Greece

  3. 3

    Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece

  1. †

    Fax: +30-2310-992433.

  2. ‡

    Fax: +30-2610-997153.

*Lung Tumor Research Section, Pulmonary Department, Aristotle University of Thessaloniki, ‘G. Papanikolaou’ Hospital, Thessaloniki, Greece

Publication History

  1. Issue published online: 24 JUL 2009
  2. Article first published online: 6 APR 2009
  3. Accepted manuscript online: 6 APR 2009 12:00AM EST
  4. Manuscript Accepted: 17 MAR 2009
  5. Manuscript Received: 23 FEB 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (213K)

Keywords:

  • lung cancer;
  • bone metastasis;
  • bisphosphonates;
  • zoledronic acid;
  • N-telopeptide;
  • type I collagen

Abstract

Bone metastases occur in 20–40% of patients with lung cancer. Recent studies demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung tumors, which may influence the survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa®), a 3rd generation BP, with a focus on the survival, time to progression and pain effect in lung cancer patients with bone metastases. Lung cancer patients (n = 144, Stage IV) with evidence of metastasis bone scan were included. Eighty-seven of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 patients received no ZOL (Group B). All patients were treated with a combination chemotherapy consisted of docetaxel 100 mg/m2 and carboplatin AUC = 6. It was found that Group A had a statistically significant longer survival (p < 0.01) when compared to Group B. A statistically significant positive correlation was found between the number of cycles of therapy with ZOL and total patient survival (p < 0.01, Pearson correlation) and time to progression (p < 0.01). Pain effect of ZOL had no significant difference between the 2 groups of patients (p > 0.05). Urine N-telopeptide of type I collagen (NTx) levels decreased in patients with NTx ≤ 29 nM BCE/mM creatinine at baseline after treatment with ZOL. The results of our study suggest that the addition of ZOL increases overall survival in lung cancer patients with bone metastases. The longer period of receiving ZOL, the better effect on survival and time to progression. © 2009 UICC

View Full Article (HTML) Get PDF (213K)